口服短程方案治疗肺结核利福平耐药(TB-PRACTECAL):一项开放标签、随机、对照、2B-3期、多臂、多中心、非劣效性试验
TB-PRACTECAL是在乌兹别克斯坦、白俄罗斯和南非7个中心开展的开放标签、随机、对照、多臂、多中心、非劣效性试验,纳入552例≥15岁肺结核利福平耐药患者。第二阶段比较24周全口服贝达喹啉+普托马尼+利奈唑胺+莫西沙星(BPaLM)与36-80周标准治疗。改良意向治疗人群中,BPaLM组72周不良结局16/137(12%)vs 标准治疗组56/137(41%),风险差-29.2个百分点(96.6%CI -39.8至-18.6),非劣效和优效P<0.0001;≥3级不良事件或严重不良事件BPaLM组34/151(23%)vs 标准治疗组72/151(48%),风险差-25.2个百分点(96.6%CI -36.4至-13.9)。作者结论认为24周全口服BPaLM方案安全有效,2022年已纳入WHO指南。
要点
- 改良意向治疗人群中,BPaLM组72周不良结局16/137(12%)vs 标准治疗组56/137(41%),风险差-29.2个百分点(96.6%CI -39.8至-18.6),非劣效和优效P<0.0001。
- BPaLM组≥3级不良事件或严重不良事件34/151(23%)vs 标准治疗组72/151(48%),风险差-25.2个百分点(96.6%CI -36.4至-13.9)。
- 标准治疗组72周内报告5例死亡,其中1例(COVID-19肺炎)与治疗无关,4例(急性胰腺炎、自杀、猝死、心源性猝死)判定与治疗相关。
- 非劣效界值为12%;BPaLM为24周全口服方案,标准治疗为36-80周。
- 作者结论:24周全口服BPaLM方案安全有效,2022年已纳入WHO指南,将成为青少年和成人肺结核利福平耐药的首选方案。
适用人群与场景
- 年龄≥15岁、肺结核利福平耐药的患者,纳入乌兹别克斯坦、白俄罗斯和南非的7个医院和社区中心。
- 改良意向治疗人群为所有利福平耐药且至少接受一剂研究药物的参与者。
诊断标准与关键阈值
- 非劣效界值为12%。
- 主要结局为随机化后72周复合不良结局(治疗失败、死亡、治疗中断、疾病复发或失访)的百分比。
- 改良意向治疗人群:所有利福平耐药且至少接受一剂研究药物的参与者;符合方案人群:改良意向治疗人群中排除未完成方案依从性疗程(非因治疗失败或死亡)及因违反至少一项纳入或排除标准而早期停药者。
处置流程与药物剂量
- BPaLM方案:24周口服贝达喹啉、普托马尼、利奈唑胺和莫西沙星。
- 标准治疗:36-80周标准治疗。
- BPaL方案:24周口服贝达喹啉、普托马尼和利奈唑胺。
- BPaLC方案:BPaL加利福喷丁(clofazimine)。
- 第一阶段按1:1:1:1随机分配至标准治疗、BPaL、BPaLC或BPaLM;第二阶段按1:1随机分配至标准治疗或BPaLM。
研究设计与关键结果
- 开放标签、随机、对照、多臂、多中心、非劣效性试验,在乌兹别克斯坦、白俄罗斯和南非7个中心开展;2017年1月16日至2021年3月18日筛查680例,随机分配552例(标准治疗组152例、BPaLM组151例、BPaLC组126例、BPaL组123例)。
- 第二阶段报告标准治疗组和BPaLM组:安全性人群BPaLM组151例、标准治疗组151例;改良意向治疗人群BPaLM组138例、标准治疗组137例。
- 改良意向治疗人群中,BPaLM组可评估结局的137例中16例(12%)报告不良结局,标准治疗组137例中56例(41%)报告不良结局,风险差-29.2个百分点(96.6%CI -39.8至-18.6),非劣效和优效P<0.0001。
- BPaLM组151例中34例(23%)发生≥3级不良事件或严重不良事件,标准治疗组151例中72例(48%)发生,风险差-25.2个百分点(96.6%CI -36.4至-13.9)。
- 标准治疗组72周内报告5例死亡,其中1例(COVID-19肺炎)与治疗无关,4例(急性胰腺炎、自杀、猝死、心源性猝死)判定与治疗相关。
证据类型、等级与局限
- 证据类型:开放标签、随机、对照、多臂、多中心、非劣效性2B-3期试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为24周全口服BPaLM方案安全有效,2022年已纳入WHO指南,这些发现将是BPaLM成为青少年和成人肺结核利福平耐药首选方案的关键。
指南或共识出处
- WHO指南(2022年纳入BPaLM方案治疗肺结核利福平耐药)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Around 500 000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are needed. Following an interim analysis, we report the final safety and efficacy outcomes of the TB-PRACTECAL trial, evaluating the safety and efficacy of oral regimens for the treatment of rifampicin-resistant tuberculosis.
METHODS: This open-label, randomised, controlled, multi-arm, multicentre, non-inferiority trial was conducted at seven hospital and community sites in Uzbekistan, Belarus, and South Africa, and enrolled participants aged 15 years and older with pulmonary rifampicin-resistant tuberculosis. Participants were randomly assigned, in a 1:1:1:1 ratio using variable block randomisation and stratified by trial site, to receive 36-80 week standard care; 24-week oral bedaquiline, pretomanid, and linezolid (BPaL); BPaL plus clofazimine (BPaLC); or BPaL plus moxifloxacin (BPaLM) in stage one of the trial, and in a 1:1 ratio to receive standard care or BPaLM in stage two of the trial, the results of which are described here. Laboratory staff and trial sponsors were masked to group assignment and outcomes were assessed by unmasked investigators. The primary outcome was the percentage of participants with a composite unfavourable outcome (treatment failure, death, treatment discontinuation, disease recurrence, or loss to follow-up) at 72 weeks after randomisation in the modified intention-to-treat population (all participants with rifampicin-resistant disease who received at least one dose of study medication) and the per-protocol population (a subset of the modified intention-to-treat population excluding participants who did not complete a protocol-adherent course of treatment (other than because of treatment failure or death) and those who discontinued treatment early because they violated at least one of the inclusion or exclusion criteria). Safety was measured in the safety population. The non-inferiority margin was 12%. This trial is registered with ClinicalTrials.gov, NCT02589782, and is complete.
FINDINGS: Between Jan 16, 2017, and March 18, 2021, 680 patients were screened for eligibility, of whom 552 were enrolled and randomly assigned (152 to the standard care group, 151 to the BPaLM group, 126 to the BPaLC group, and 123 to the BPaL group). The standard care and BPaLM groups proceeded to stage two and are reported here, post-hoc analyses of the BPaLC and BPaL groups are also reported. 151 participants in the BPaLM group and 151 in the standard care group were included in the safety population, with 138 in the BPaLM group and 137 in the standard care group in the modified intention-to-treat population. In the modified intention-to-treat population, unfavourable outcomes were reported in 16 (12%) of 137 participants for whom outcome was assessable in the BPaLM group and 56 (41%) of 137 participants in the standard care group (risk difference -29·2 percentage points [96·6% CI -39·8 to -18·6]; non-inferiority and superiority p<0·0001). 34 (23%) of 151 participants receiving BPaLM had adverse events of grade 3 or higher or serious adverse events, compared with 72 (48%) of 151 participants receiving standard care (risk difference -25·2 percentage points [96·6% CI -36·4 to -13·9]). Five deaths were reported in the standard care group by week 72, of which one (COVID-19 pneumonia) was unrelated to treatment and four (acute pancreatitis, suicide, sudden death, and sudden cardiac death) were judged to be treatment-related.
INTERPRETATION: The 24-week, all-oral BPaLM regimen is safe and efficacious for the treatment of pulmonary rifampicin-resistant tuberculosis, and was added to the WHO guidance for treatment of this condition in 2022. These findings will be key to BPaLM becoming the preferred regimen for adolescents and adults with pulmonary rifampicin-resistant tuberculosis.
FUNDING: Médecins Sans Frontières.
参考来源
- Nyang'wa BT, Berry C, Kazounis E, et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med. 2023. PMID: 37980911. doi:10.1016/S2213-2600(23)00389-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。